Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01211
|
|||||
Drug Name |
Nimodipine
|
|||||
Synonyms |
1,4-Dihydro-2,6-dimethyl-4-(3′-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide; Admon; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bay-E 9736; Bay-e-9736; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Brainal; Calnit; Cantabria Brand of Nimodipine; DRG-0139; EG-1961; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; Kenesil; Modus; N-149; NIMOTOP (TN); NimoGel; Nimodipin Hexal; Nimodipin ISIS; Nimodipin-ISIS; NimodipinISIS; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Nimodipino; Nimodipino Bayvit; Nimodipino [INN-Spanish]; Nimodipinum; Nimodipinum [INN-Latin]; Nimotop; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Periplum; Periplum, Nimotop, BRN 0459792, DRG-0139; Remontal; Vita Brand of Nimodipine
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Cerebral vasospasm [ICD11:BA85.Z] | Approved | [1] | |||
Therapeutic Class |
Vasodilator Agents
|
|||||
Structure |
|
![]() |
||||
3D MOL | 2D MOL | |||||
Formula |
C21H26N2O7
|
|||||
Canonical SMILES |
CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
|
|||||
InChI |
InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
|
|||||
InChIKey |
UIAGMCDKSXEBJQ-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 66085-59-4
|
|||||
Pharmaceutical Properties | Molecular Weight | 418.4 | Topological Polar Surface Area | 120 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 9 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 8 | |||
XLogP |
3.1
|
|||||
PubChem CID | ||||||
PubChem SID |
11119999
,11120487
,11120975
,11121462
,11121942
,11147082
,11341987
,11362170
,11362531
,11364815
,11365093
,11367377
,11367655
,11369939
,11370333
,11370334
,11371732
,11373256
,11374401
,11375817
,11378106
,11466946
,11468066
,11485200
,11486721
,11487572
,11489378
,11490582
,11492606
,11495694
,11528721
,12013716
,14831516
,17405450
,24277858
,26612490
,26663021
,26680672
,26747118
,26747119
,3153214
,4444853
,596563
,6951262
,7404101
,7847504
,7980128
,8152770
,855566
,9476
|
|||||
ChEBI ID |
CHEBI:7575
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
References | ||||||
1 | Nimodipine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. |
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.